Here's Why you Should Retain Nevro Stock in Your Portfolio Now

Nevro (NVRO) is well-poised for growth in the coming quarters, courtesy of strength in Senza and diversification plans regarding product portfolio. The optimism, led by a decent second-quarter 2024 performance and continued focus on research and development activities, is expected to contribute further. However, concerns regarding softness in the spinal cord stimulation (SCS) market and dependence on thirdparty payers persist. This Zacks Rank #3 (Hold) company's shares have lost 74.9% in the year-to-date pe ...